Xu Zheng, Li Na, Chen Yingli, Zhang Wenrui, Zhu Wanying
State Key Laboratory of Materials-Oriented Chemical Engineering, College of Food Science and Light Industry, Nanjing Tech University, Nanjing 211816, Jiangsu, China.
Sheng Wu Gong Cheng Xue Bao. 2020 Dec 25;36(12):2767-2778. doi: 10.13345/j.cjb.200201.
Human milk oligosaccharides (HMO) are important immunoactive components found in breast milk. Scientific research proves that HMOs are significantly beneficial for infant health. 2'-fucosyllactose (2'-FL) is the major component of HMO, which obtained growing attentions from food industry. Besides, 3-fucosyllactose (3-FL) is another important fucosyllactose and it has a similar synthetic route comparing to 2'-FL. Thus, research of the two HMO components has interactive effects for each other. Recently, numerous publications are available for 2'-FL and 3-FL. The microbial cell factory is able to massively produce fucosyllactose via an efficient way, which will show considerable influences in dairy industry. In this paper, we review recent studies on 2'-FL and 3-FL, and discuss their prospects according to published literature and patents.
人乳寡糖（HMO）是母乳中重要的免疫活性成分。科学研究证明，HMO对婴儿健康有显著益处。2'-岩藻糖基乳糖（2'-FL）是HMO的主要成分，受到食品工业越来越多的关注。此外，3-岩藻糖基乳糖（3-FL）是另一种重要的岩藻糖基乳糖，其合成途径与2'-FL相似。因此，对这两种HMO成分的研究相互有交互作用。最近，有大量关于2'-FL和3-FL的出版物。微生物细胞工厂能够通过高效的方式大量生产岩藻糖基乳糖，这将对乳制品行业产生重大影响。在本文中，我们综述了关于2'-FL和3-FL的最新研究，并根据已发表的文献和专利讨论它们的前景。
